Information regarding Akynzeo in Guatemala is limited in the provided documents. To find specific details about Akynzeo's availability, regulatory status, or any associated patents in Guatemala, one would typically need to consult local health authority records or specialized pharmaceutical databases. DrugPatentWatch.com offers a resource for tracking drug patents globally, which may include information relevant to specific countries [1].
What is Akynzeo used for?
Akynzeo is a combination medication used for the prevention of chemotherapy-induced nausea and vomiting (CINV). It contains netupitant, a neurokinin-1 (NK1) receptor antagonist, and palonosetron, a serotonin-5-HT3 receptor antagonist [2]. This dual mechanism of action targets different pathways involved in nausea and vomiting, offering comprehensive protection against both acute and delayed CINV [3].
When was Akynzeo approved?
Akynzeo received its first approval in Europe in 2015 [2]. Subsequent approvals have occurred in other regions, including the United States, where it was approved in 2015 as well [4].
How does Akynzeo work?
Akynzeo works by blocking two key receptors involved in the nausea and vomiting response to chemotherapy. Netupitant inhibits the NK1 receptor, which plays a critical role in the delayed phase of CINV. Palonosetron blocks the 5-HT3 receptor, primarily targeting the acute phase of CINV. By addressing both phases and utilizing different receptor pathways, Akynzeo aims to provide sustained relief from chemotherapy-induced emesis [2, 3].
What are the potential side effects of Akynzeo?
Common side effects reported with Akynzeo include fatigue, headache, constipation, and indigestion [2]. As with any medication, patients should discuss potential risks and side effects with their healthcare provider.
How does Akynzeo compare to other anti-emetic drugs?
Akynzeo offers a fixed combination of two distinct anti-emetic mechanisms, netupitant and palonosetron. Other anti-emetic regimens might involve different combinations of drugs, such as a 5-HT3 antagonist alone or in combination with a corticosteroid. The fixed-dose combination of Akynzeo simplifies administration and aims to provide robust protection against CINV by targeting both acute and delayed phases through distinct pathways [2, 3].
When do Akynzeo patents expire?
Patent expiry dates for pharmaceuticals can vary significantly by country and are subject to extensions and legal challenges. DrugPatentWatch.com is a resource that tracks patent information for drugs, which would allow for specific searches regarding Akynzeo's patent status in various regions [1]. Without specific country data, general expiry timelines cannot be provided.
Sources:
[1] DrugPatentWatch.com
[2] European Medicines Agency (EMA) assessment report for Akynzeo.
[3] Spinaci, G., et al. (2013). Netupitant and palonosetron, a fixed combination for the prevention of chemotherapy-induced nausea and vomiting. Expert Opinion on Pharmacotherapy, 14(17), 2377-2386.
[4] U.S. Food and Drug Administration (FDA) approval information for Akynzeo.